Ocular Hypertension and the Risk of Blindness

A. van Gestel; C.A.B. Webers; H.J.M. Beckers; A. Peeters; J.L. Severens; J.S.A.G. Schouten

doi:10.1097/IJG.0b013e318287ac75

Ocular Hypertension and the Risk of Blindness

A. van Gestel, C.A.B. Webers, H.J.M. Beckers, A. Peeters, J.L. Severens, J.S.A.G. Schouten^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Purpose: To estimate the risk of blindness in patients with ocular hypertension (OHT) using an appropriate model and current empirical data.

Design: A Markov model with data from a systematic literature review.

Methods: A Markov model with 3 health states was built: OHT, primary open-angle glaucoma (POAG), and unilateral blindness. Literature was searched for reports on conversion from OHT to POAG and progression from POAG to blindness, to estimate a range of annual conversion and progression probabilities. The model had a cycle length of 1 year.

Results: The 15-year risk estimates ranged from 3.1% to 9.4% in untreated, and from 0.9% to 8.6% in treated patients with OHT. The ranges were the result of differences in patient populations, treatments, and outcome definitions in currently available empirical data.

Conclusions: The best estimates of the 15-year risk of unilateral blindness in patients with OHT, based on the currently available empirical data and an appropriate model, show that the risk is

Original language	English
Pages (from-to)	9-11
Number of pages	3
Journal	Journal of Glaucoma
Volume	24
Issue number	1
Early online date	20 Mar 2013
DOIs	https://doi.org/10.1097/IJG.0b013e318287ac75
Publication status	Published - 1 Jan 2015

Keywords

ocular hypertension
blindness
Markov model
OPEN-ANGLE GLAUCOMA
TERM CLINICAL-TRIAL
VISUAL-FIELD LOSS
RANDOMIZED TRIAL
TIMOLOL THERAPY
MANAGEMENT
SUSPECTS

Access to Document

10.1097/IJG.0b013e318287ac75

Cite this

@article{defbf92dbf7f4a078fb741f39b415868,

title = "Ocular Hypertension and the Risk of Blindness",

abstract = "Purpose: To estimate the risk of blindness in patients with ocular hypertension (OHT) using an appropriate model and current empirical data.Design: A Markov model with data from a systematic literature review.Methods: A Markov model with 3 health states was built: OHT, primary open-angle glaucoma (POAG), and unilateral blindness. Literature was searched for reports on conversion from OHT to POAG and progression from POAG to blindness, to estimate a range of annual conversion and progression probabilities. The model had a cycle length of 1 year.Results: The 15-year risk estimates ranged from 3.1% to 9.4% in untreated, and from 0.9% to 8.6% in treated patients with OHT. The ranges were the result of differences in patient populations, treatments, and outcome definitions in currently available empirical data.Conclusions: The best estimates of the 15-year risk of unilateral blindness in patients with OHT, based on the currently available empirical data and an appropriate model, show that the risk is",

keywords = "ocular hypertension, blindness, Markov model, OPEN-ANGLE GLAUCOMA, TERM CLINICAL-TRIAL, VISUAL-FIELD LOSS, RANDOMIZED TRIAL, TIMOLOL THERAPY, MANAGEMENT, SUSPECTS",

author = "{van Gestel}, A. and C.A.B. Webers and H.J.M. Beckers and A. Peeters and J.L. Severens and J.S.A.G. Schouten",

year = "2015",

month = jan,

day = "1",

doi = "10.1097/IJG.0b013e318287ac75",

language = "English",

volume = "24",

pages = "9--11",

journal = "Journal of Glaucoma",

issn = "1057-0829",

publisher = "LIPPINCOTT WILLIAMS & WILKINS",

number = "1",

}

TY - JOUR

T1 - Ocular Hypertension and the Risk of Blindness

AU - van Gestel, A.

AU - Webers, C.A.B.

AU - Beckers, H.J.M.

AU - Peeters, A.

AU - Severens, J.L.

AU - Schouten, J.S.A.G.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Purpose: To estimate the risk of blindness in patients with ocular hypertension (OHT) using an appropriate model and current empirical data.Design: A Markov model with data from a systematic literature review.Methods: A Markov model with 3 health states was built: OHT, primary open-angle glaucoma (POAG), and unilateral blindness. Literature was searched for reports on conversion from OHT to POAG and progression from POAG to blindness, to estimate a range of annual conversion and progression probabilities. The model had a cycle length of 1 year.Results: The 15-year risk estimates ranged from 3.1% to 9.4% in untreated, and from 0.9% to 8.6% in treated patients with OHT. The ranges were the result of differences in patient populations, treatments, and outcome definitions in currently available empirical data.Conclusions: The best estimates of the 15-year risk of unilateral blindness in patients with OHT, based on the currently available empirical data and an appropriate model, show that the risk is

AB - Purpose: To estimate the risk of blindness in patients with ocular hypertension (OHT) using an appropriate model and current empirical data.Design: A Markov model with data from a systematic literature review.Methods: A Markov model with 3 health states was built: OHT, primary open-angle glaucoma (POAG), and unilateral blindness. Literature was searched for reports on conversion from OHT to POAG and progression from POAG to blindness, to estimate a range of annual conversion and progression probabilities. The model had a cycle length of 1 year.Results: The 15-year risk estimates ranged from 3.1% to 9.4% in untreated, and from 0.9% to 8.6% in treated patients with OHT. The ranges were the result of differences in patient populations, treatments, and outcome definitions in currently available empirical data.Conclusions: The best estimates of the 15-year risk of unilateral blindness in patients with OHT, based on the currently available empirical data and an appropriate model, show that the risk is

KW - ocular hypertension

KW - blindness

KW - Markov model

KW - OPEN-ANGLE GLAUCOMA

KW - TERM CLINICAL-TRIAL

KW - VISUAL-FIELD LOSS

KW - RANDOMIZED TRIAL

KW - TIMOLOL THERAPY

KW - MANAGEMENT

KW - SUSPECTS

U2 - 10.1097/IJG.0b013e318287ac75

DO - 10.1097/IJG.0b013e318287ac75

M3 - Article

SN - 1057-0829

VL - 24

SP - 9

EP - 11

JO - Journal of Glaucoma

JF - Journal of Glaucoma

IS - 1

ER -